Titan Medical Inc.

Corporate Presentation

TSX: TMD | OTCQX: TITXF

A final base shelf prospectus containing important information relating to the securities described in this document has been filed with the securities regulatory authorities in Ontario, British Columbia and Alberta. A copy of the final base shelf prospectus, any amendment to the final base shelf prospectus and any applicable shelf prospectus supplement that has been filed, is required to be delivered with this document.

This document does not provide full disclosure of all material facts relating to the securities offered. Investors should read the final base shelf prospectus, any amendment and any applicable shelf prospectus supplement for disclosure of those facts, especially risk factors relating to the securities offered, before making an investment decision.

November 5, 2015

Forward Looking Statements

This presentation contains "forward-looking information", within the meaning of applicable Canadian securities laws, concerning anticipated developments and events which Titan Medical Inc. (the "Company") has a reasonable basis to believe may occur in the future. These forward-looking statements are made as of the date of this presentation. Forward-looking statements are frequently, but not always, identified by words such as "expects", "expectation", "anticipates", "believes", "intends", "estimates", "predicts", "continues", "potential", "targeted", "plans", "possible" and similar expressions (including negative and grammatical variations), or statements that events, conditions or results "will", "may", "could", "would", "should" or "can" occur or be achieved. Any forward-looking statements or statements of "belief" represent our estimates only as of the date of this presentation and should not be relied upon as representing our estimates as of any subsequent date. These forward-looking statements may concern anticipated developments in the Company's operations in future periods, the adequacy of the Company's financial resources and other events or conditions that may occur in the future, and include, without limitation, statements regarding:

- the Company's intention with respect to updating any forward-looking statement after the date on which such statement is made or to reflect the occurrence of unanticipated events;
- the Company's expectation with respect to continuing animal feasibility and commencing cadaver studies;
- the Company's expectation with respect to the initiation of human clinical trials and initial regulatory submissions;
- the Company's expectation with respect to launching a commercial product in certain jurisdictions;
- the Company's plans to develop and commercialize the SPORT™ Surgical System and the estimated incremental costs (including cost and timing of achieving the development milestones disclosed herein);
- the Company's intentions with respect to initiating marketing activities following receipt of the applicable regulatory approvals;
- the surgical indications for the SPORT™ Surgical System and the benefits of the system;
- the Company's intention to continue to assess specialized skill and knowledge requirements and recruitment of qualified personnel and partners;
- the Company's belief that the materials and parts necessary for the manufacture of a clinical-grade SPORT™ Surgical System will be available in the marketplace;
- the Company's filing of patent applications to expand its intellectual property portfolio as technologies are developed or refined;
- the Company's seeking of licensing opportunities to expand its intellectual property portfolio;
- the Company's intended use of proceeds of the offering;
- the Company's intention with respect to not paying any cash dividends on common shares in the foreseeable future;
- the Company's intention to retain future earnings, if any, to finance expansion and growth;
- the potential market for warrants or units; and
- over-allotment options or other transactions which would stabilize or maintain the market price of the Company's securities.

Forward-looking statements are statements about the future and are inherently uncertain, and actual results of the Company or other future events or conditions may differ materially from those reflected in the forward-looking statements due to a variety of risks, uncertainties and other factors, including those referred to in this presentation, or listed from time to time in our reports, public disclosure documents and other filings with the securities commissions in Canada. These risks include, but are not limited to:

- current global financial conditions;
- dependence on key personnel;
- conflicts of interest;
- the Company's ability to obtain additional financing;
- strategic alliances;
- uncertainty as to product development and commercialization milestones;
- results of operations;
- competition;
- rapidly changing markets;
- uncertain market or uncertain acceptance of the Company's technology;
- technological advancements;
- intellectual property protection and infringement;
- ability to license other intellectual property rights;
- insurance and uninsured risks;
- product and services not completely developed;
- government regulation;
- changes in government policy;
- regulatory approval;
- changes in accounting and tax rules;
- contingent liabilities;
- manufacturing risks;
- product defect risk;
- profitability;
- supplier risk;
- history of losses;
- stock price volatility;
- future share sales;
- limited operating history;
- fluctuating financial results; and
- currency fluctuations.

Forward-looking statements are based on a number of assumptions which may prove to be incorrect, including but not limited to assumptions about:

- general business and current global economic conditions;
- future success of current research and development activities;
- achieving development and commercial milestones;
- competition;
- changes to tax rates and benefits;
- the availability of financing;
- the Company's and competitors' costs of production and operations;
- the Company's ability to attract and retain skilled employees;
- the Company's ongoing relations with its third party service providers;
- the design of the SPORT™ Surgical System and related platforms and equipment;
- the progress and timing of the development of the SPORT™ Surgical System;
- costs related to the development, completion and potential commercialization of the SPORT™ Surgical System;
- receipt of all applicable regulatory approvals;
- estimates and projections regarding the robotic surgery equipment industry;
- protection over the Company's intellectual property rights;
- market acceptance of the Company's systems under development; and
- the type of specialized skill and knowledge required to develop the SPORT™ Surgical System and the Company's access to such specialized skill and knowledge.

We caution that the foregoing list of important factors and assumptions is not exhaustive. Although the Company has attempted to identify on a reasonable basis important factors and assumptions related to forward-looking statements, there can be no assurance that forward-looking statements will prove to be accurate, as events or circumstances or other factors could cause actual results to differ materially from those estimated or projected and expressed in, or implied by, these forward-looking statements. Other than as specifically required by law, the Company undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made, or to reflect the occurrence of unanticipated events, whether as a result of new information, future events or results or otherwise. Accordingly, readers should not place undue reliance on forward-looking statements.

Further details with respect to the above are included in the Company's base shelf prospectus dated August 18, 2015 and the prospectus supplement to which the current offering relates.

The SPORT™ Surgical System



Artist/CAD Rendering of SPORT™ Surgical System

*The SPORT™ Surgical System has not been approved for sale or use by any regulatory authority, including the Food and Drug Administration (the “FDA”).

The SPORT™ Surgical System

- The SPORT™ Surgical System delivers next generation computer-assisted robotic surgical technology that builds on traditional robotic surgical features:
  - Tele-operation
  - 3D stereoscopic imaging
  - Restoration of instinctive control
- The SPORT™ Surgical System is designed to provide:
  - An advanced workstation incorporating a 3D high definition display providing a more ergonomic friendly user interface
  - Improved instrument dexterity

The SPORT™ Surgical System

Two Main Components:

Surgeon Workstation


Patient Cart



SPORT™ Surgical System CAD Rendering

Surgeon Workstation

- Advanced ergonomic surgeon interface to allow the surgeon to more comfortably control the surgical platform.
  - The system adapts to the surgeon instead of having the surgeon adapt to the system
- Enhanced Functionality/Features:
  - 3D high definition flat panel display
  - Custom designed master controllers
  - Second display for delivering ancillary information
  - Data collection and analytics



SPORT™ Surgical System
Workstation CAD Rendering

Robotic Platform/Patient Cart

- Designed for optimal configurability for a variety of surgical indications and to be maneuvered around operating room and surgical centers
- Incorporates an Insertion Tube for insertion into a patient during a surgical procedure, including:
  - A stereoscopic camera module
  - Insertable robotic instruments



SPORT™ Surgical System Patient Cart CAD Rendering

Camera Module and Instruments

- Stereoscopic Camera Module
  - Custom design allows a 19 mm diameter Insertion Tube enabling an incision size of approximately 25 mm
  - Multi-direction movement
    - Collapsible/Expandable
    - Pan and Tilt
    - Digital Zoom
- Robotic Instrument Arms
  - Multi-articulating to allow for “snake-like” movement
  - Single-patient use tool tips



SPORT™ Tools

- Single-Patient Use Tool Tips
  - Sterile
  - No Reprocessing Required
  - First Use Quality Every Case



- Reposable Robotic Instruments
  - More use cases for each instrument arm
  - Reduces per case cost



SPORT™ Training & Assessment

- Under development with the James and Sylvia Earl, Simulation to Advance Innovation and Learning (SAIL) Center at Anne Arundel Medical Center (AAMC) in Annapolis, MD

Training Curriculum	
Cognitive pre-training	Knowledge Acquisition
Psychomotor skills training	Technical Skills Acquisition
Team training	Choreography & Communication
Troubleshooting	Crisis Mitigation
Overview of safety	Optimal Skills and Teamwork

Learning Experiences

Assessment Tools

Post-Training Assessment	
Design assessment tools	Define: skills, setting, scoring method, scenarios, & train raters
Validate assessment tools	Construct Validity, Predictive Validity

Regulatory Update

- Agreement completed with a Contract Research Organization (CRO) to implement Early Feasibility Human Study – September 2015
- Contracted with a Notified Body – July 2015

Development Milestones

Development Milestones	Estimated Cost (in U.S. $)	Schedule for Milestone Completion	Comments
Alpha commercial prototype design complete (Design of prototype suitable for ongoing tissue testing)	-	Q1 2014	Completed
Alpha commercial prototype built	-	Q2 2014	Completed
Tissue testing (Testing performance of individual features and functionality)	-	Q2 2014	Completed
Design and test of feasibility prototype complete (Demonstrate feasibility for next generation console and advanced instruments)	-	Q1 2015	Completed
Units built and ready for engineering verification (Prototype is formally tested to meet previously defined specifications)	(2 milestones)		
Build 2 engineering verification units	$14 million	Q4 2015 Expected	
Build 5 first in-human units	$9 million	Q1 2016 Expected	

Development Milestones – Cont'd

Development Milestones	Estimated Cost (in U.S. $)	Schedule for Milestone Completion	Comments
Early human feasibility report complete (Human clinical cases utilizing units are tested under engineering verification)	**$24 million (2 milestones)**	**Q2 2016 Expected**	**First in human studies confirm capabilities of SPORT™ Surgical System for expanded use. Build 4 additional human clinical trial units.**
Audit for CE Mark approval commenced		Q2 2016 Expected	
Pivotal human clinical trial commenced	$5 million	Q3 2016 Expected	
Pivotal human clinical trial completed and 510(k) application submitted to FDA	$5 million (3 milestones)	Q4 2016 Expected	
Outside U.S. commercial launch (Pending CE Mark approval)		Q4 2016 Expected	
U.S. commercial launch (Pending 510(k) market clearance)		Mid-2017 Expected	
TOTAL	U.S. $57 million		

(in US Dollars except warrants and options exercisable in Canadian dollars)


Financial Snapshot

TSX: TMD | OTCQX: TITXF

June 30, 2015	
Share Price (TMD)[1]	U.S. $1.31
Cash and cash equivalents	U.S. $19.9 million
Shares outstanding	102.6 million (104.6 million FD*)
Market value	134.4 million (U.S. $137.1 million FD*)
Management ownership	6.21%

[1] Closing price on June 30, 2015, converted into U.S. dollars using the June 30, 2015 exchange rate of 0.8037.
**Fully diluted includes, under the Treasury Stock method, an additional 2,894,355 options with a weighted-average exercise price of CDN $1.28.*
In addition, 3,665,900 warrants (@CDN $1.85 expiring December 10, 2015), 5,121,500 warrants (@CDN $2.00 expiring June 21, 2016), 3,484,500 warrants (@CDN $1.75 expiring December 22, 2016), 390,729 warrants (@CDN $1.77 expiring March 14, 2017), 5,260,705 warrants (@CDN $1.25 expiring March 13, 2018), 8,317,856 warrants (@CDN $2.00 expiring February 19, 2017), and an additional 12,346,914 warrants (@CDN $2.75 expiring April 23, 2017).

Stock Performance



The following table shows the value of CDN$100 invested in Common Shares on December 31, 2009 compared to CDN$100 invested in the S&P/TSX Composite Index*:
*All amounts in Canadian $.

	31-Dec-09	31-Dec-10	31-Dec-11	31-Dec-12	31-Dec-13	31-Dec-14
Titan Medical Inc.	100.00	355.00	337.50	300.00	237.50	350.00
S&P/TSX Composite Index	100.00	114.45	101.78	105.85	115.97	124.57